S2k guideline: Rosacea.
Journal
Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
ISSN: 1610-0387
Titre abrégé: J Dtsch Dermatol Ges
Pays: Germany
ID NLM: 101164708
Informations de publication
Date de publication:
08 2022
08 2022
Historique:
received:
09
03
2022
accepted:
10
06
2022
pubmed:
6
8
2022
medline:
18
8
2022
entrez:
5
8
2022
Statut:
ppublish
Résumé
This updated and upgraded S2k guideline deals with the diagnosis and treatment of rosacea, which is a common, chronic inflammatory skin disease mostly affecting the face. Initially, rosacea is characterized by recurrent erythema, telangiectasia and flushing. Later, the inflammatory component predominates, with persistent erythema with follicular papules, papulopustules and pustules. The development of phyma, which usually occurs on the acral localizations, is the most severe manifestation. For the treatment of rosacea, the interdisciplinary guideline committee, with representatives of the German Dermatological Society (DDG), the Professional Association of German Dermatologists (BVDD), the German Opthalmological Society (DOG), the Society for Dermopharmacy (GD), the Swiss Society for Dermatology and Venereology (SGDV) and the German Rosacea Aid e. V., recommends the avoidance of trigger factors and topical applications of metronidazole, azelaic acid or ivermectin. For symptomatic treatment of persistent centrofacial erythema, the topical vasoconstrictors brimonidine or oxymetazoline can also be used. Systemic therapy is recommended for therapy-resistant and severe forms of rosacea papulopustulosa. The drug of choice is low-dose doxycycline. Alternatively, low-dose isotretinoin can be recommended. Ocular rosacea should be treated with lid margin hygiene. For topical treatment, ciclosporin eye drops, azithromycin, ivermectin or metronidazole are suggested.
Substances chimiques
Dermatologic Agents
0
Metronidazole
140QMO216E
Brimonidine Tartrate
4S9CL2DY2H
Ivermectin
70288-86-7
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1147-1165Informations de copyright
© 2022 The Authors. Journal der Deutschen Dermatologischen Gesellschaft published by John Wiley & Sons Ltd on behalf of Deutsche Dermatologische Gesellschaft.
Références
Kaminski-Hartenthaler A, Meerpohl JJ, Gartlehner G et al. [GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations]. Z Evid Fortbild Qual Gesundhwes 2014; 108: 413-20.
Reinholz M, Tietze JK, Kilian K et al. Rosazea-S1-Leitlinie. J Dtsch Dermatol Ges 2013; 11: 768-79.
Schaller M, Schofer H, Homey B et al. Rosacea Management: Update on general measures and topical treatment options. J Dtsch Dermatol Ges 2016; 14 (Suppl 6): 17-27.
Spoendlin J, Voegel JJ, Jick SS, Meier CR. A study on the epidemiology of rosacea in the U.K. Br J Dermatol 2012; 167: 598-605.
Gether L, Overgaard LK, Egeberg A, Thyssen JP. Incidence and prevalence of rosacea: a systematic review and meta-analysis. Br J Dermatol 2018; 179: 282-9.
Augustin M, Herberger K, Hintzen S et al. Prevalence of skin lesions and need for treatment in a cohort of 90 880 workers. Br J Dermatol 2011; 165: 865-73.
Alexis AF, Callender VD, Baldwin HE et al. Global epidemiology and clinical spectrum of rosacea, highlighting skin of color: Review and clinical practice experience. J Am Acad Dermatol 2019; 80: 1722-29 e7.
Elewski BE, Draelos Z, Dreno B et al. Rosacea - global diversity and optimized outcome: proposed international consensus from the Rosacea International Expert Group. J Eur Acad Dermatol Venereol 2011; 25: 188-200.
Van Steensel MAM, Badeloe S, Winnepenninckx V et al. Granulomatous rosacea and Crohn’s disease in a patient homozygous for the Crohn-associated NOD2/CARD15 polymorphism R702W. Exp Dermatol 2008; 17: 1057-8.
Yamasaki K, Di Nardo A, Bardan A et al. Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea. Nat Med. 2007; 13: 975-80.
Yamasaki K, Gallo RL. Rosacea as a disease of cathelicidins and skin innate immunity. J Investig Dermatol Symp Proc 2011; 15: 12-5.
Holmes AD, Steinhoff M. Integrative concepts of rosacea pathophysiology, clinical presentation and new therapeutics. Exp Dermatol 2017; 26: 659-67.
Steinhoff M, Schauber J, Leyden JJ. New insights into rosacea pathophysiology: a review of recent findings. J Am Acad Dermatol 2013; 69: S15-26.
Wilkin J, Dahl M, Detmar M et al. Standard classification of rosacea: Report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea. J Am Acad Dermatol 2002; 46: 584-7.
Zierl S, Guertler A, Hildebrand JA et al. A comprehensive epidemiological study of rosacea in Germany. Eur J Dermatol 2021; 31(6): 744-51.
Reinholz M, Ruzicka T, Steinhoff M et al. Pathogenese und Klinik der Rosazea als Schlüssel fur eine symptomorientierte Therapie. J Dtsch Dermatol Ges 2016; 14 (Suppl 6): 4-16.
Schaller M, Almeida LMC, Bewley A et al. Recommendations for rosacea diagnosis, classification and management: update from the global ROSacea COnsensus 2019 panel. Br J Dermatol 2020; 182: 1269-76.
Gollnick H, Blume-Peytavi U, Szabó EL et al. Systemic isotretinoin in the treatment of rosacea - doxycycline- and placebo-controlled, randomized clinical study. J Dtsch Dermatol Ges 2010; 8: 505-15.
Tan J, Almeida LM, Bewley A et al. Updating the diagnosis, classification and assessment of rosacea: recommendations from the global ROSacea COnsensus (ROSCO) panel. Br J Dermatol 2017; 176: 431-8.
van Zuuren EJ, Fedorowicz Z, Tan J et al. Interventions for rosacea based on the phenotype approach: an updated systematic review including GRADE assessments. Br J Dermatol 2019; 181: 65-79.
Williamson T, Cheng WY, McCormick N, Vekeman F. Patient preferences and therapeutic satisfaction with topical agents for rosacea: a survey-based study. Am Health Drug Benefits 2018; 11: 97-106.
Gallo RL, Granstein RD, Kang S et al. Standard classification and pathophysiology of rosacea: The 2017 update by the National Rosacea Society Expert Committee. J Am Acad Dermatol 2018; 78: 148-55.
Fowler J, Jarratt M, Moore A et al. Once-daily topical brimonidine tartrate gel 0.5 % is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicentre, randomized and vehicle-controlled studies. Br J Dermatol 2012; 166: 633-41.
Fowler J, Jr., Jackson M, Moore A et al. Efficacy and safety of once-daily topical brimonidine tartrate gel 0.5 % for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double-blind, and vehicle-controlled pivotal studies. J Drugs Dermatol 2013; 12: 650-6.
Moore A, Kempers S, Murakawa G et al. Long-term safety and efficacy of once-daily topical brimonidine tartrate gel 0.5 % for the treatment of moderate to severe facial erythema of rosacea: results of a 1-year open-label study. J Drugs Dermatol 2014; 13: 56-61.
Steinhoff M, Schmelz M, Schauber J. Facial erythema of rosacea - aetiology, different pathophysiologies and treatment options. Acta Derm Venereol 2016; 96: 579-86.
Piwnica D, Rosignoli C, de Ménonville ST et al. Vasoconstriction and anti-inflammatory properties of the selective α-adrenergic receptor agonist brimonidine. J Dermatol Sci 2014; 75: 49-54.
Gold LM, Draelos ZD. New and emerging treatments for rosacea. Am J Clin Dermatol 2015; 16: 457-61.
Patel NU, Shukla S, Zaki J, Feldman SR. Oxymetazoline hydrochloride cream for facial erythema associated with rosacea. Expert Rev Clin Pharmacol 2017; 10: 1049-54.
Draelos ZD, Gold MH, Weiss RA et al. Efficacy and safety of oxymetazoline cream 1.0 % for treatment of persistent facial erythema associated with rosacea: Findings from the 52-week open label REVEAL trial. J Am Acad Dermatol 2018; 78: 1156-63.
Kircik LH, DuBois J, Draelos ZD et al. Pivotal trial of the efficacy and safety of oxymetazoline cream 1.0 % for the treatment of persistent facial erythema associated with rosacea: findings from the first REVEAL trial. J Drugs Dermatol 2018; 17: 97-105.
Layton AM, Schaller M, Homey B et al. Brimonidine gel 0.33 % rapidly improves patient-reported outcomes by controlling facial erythema of rosacea: a randomized, double-blind, vehicle-controlled study. J Eur Acad Dermatol Venereol 2015; 29: 2405-10.
Bjerke J, Nyfors A, Austad J et al. Metronidazole (Elyzol) 1-percent cream v. placebo cream in the treatment of rosacea. Clin Trials J 1989; 26: 187-94.
Breneman D, Stewart D, Hevia O et al. A double-blind, multicenter clinical trial comparing efficacy of once-daily metronidazole 1 percent cream to vehicle in patients with rosacea. Cutis. 1998; 61: 44-7.
Yoo J, Reid DC, Kimball AB. Metronidazole in the treatment of rosacea: do formulation, dosing, and concentration matter? J Drugs Dermatol 2006; 5: 317-9.
Del Rosso JQ, Kircik LH. Update on the management of rosacea: a status report on the current role and new horizons with topical azelaic acid. J Drugs Dermatol 2014; 13: s101-7.
Del Rosso JQ. Azelaic acid topical formulations: differentiation of 15 % gel and 15 % foam. J Clin Aesthet Dermatol 2017; 10: 37-40.
Draelos ZD, Elewski B, Staedtler G, Havlickova B. Azelaic acid foam 15 % in the treatment of papulopustular rosacea: a randomized, double-blind, vehicle-controlled study. Cutis 2013; 92: 306-17.
Gupta AK, Gover MD. Azelaic acid (15 % gel) in the treatment of acne rosacea. Int J Dermatol 2007; 46: 533-8.
Thiboutot D, Thieroff-Ekerdt R, Graupe K. Efficacy and safety of azelaic acid (15 %) gel as a new treatment for papulopustular rosacea: results from two vehicle-controlled, randomized phase III studies. J Am Acad Dermatol 2003; 48: 836-45.
Bjerke R, Fyrand O, Graupe K. Double-blind comparison of azelaic acid 20 % cream and its vehicle in treatment of papulo-pustular rosacea. Acta Derm Venereol 1999; 79: 456-9.
Leyer A, Rieg G, Müller M et al. Ivermectin zur Behandlung der Skabies norwegica bei AIDS Patienten. Ein neues Therapiekonzept - dargestellt an 2 Fallbeispielen. AIDS-FORSCHUNG (AIFO). 1994; 9: 608.
Zhao YE, Wu LP, Peng Y, Cheng H. Retrospective analysis of the association between Demodex infestation and rosacea. Arch Dermatol 2010; 146: 896-902.
Steinhoff M, Buddenkotte J, Aubert J et al. Clinical, cellular, and molecular aspects in the pathophysiology of rosacea. J Investig Dermatol Symp Proc 2011; 15: 2-11.
Reinholz M, Ruzicka T, Steinhoff M et al. Pathogenesis and clinical presentation of rosacea as a key for a symptom-oriented therapy. J Dtsch Dermatol Ges 2016; 14 (Suppl 6): 4-15.
Stein L, Kircik L, Fowler J et al. Efficacy and safety of ivermectin 1 % cream in treatment of papulopustular rosacea: results of two randomized, double-blind, vehicle-controlled pivotal studies. J Drugs Dermatol 2014; 13: 316-23.
Schaller M, Kemény L, Havlickova B et al. A randomized phase 3b/4 study to evaluate concomitant use of topical ivermectin 1 % cream and doxycycline 40-mg modified-release capsules, versus topical ivermectin 1 % cream and placebo in the treatment of severe rosacea. J Am Acad Dermatol 2020; 82: 336-43.
van Zuuren EJ, Arents BWM, van der Linden MMD et al. Rosacea: new concepts in classification and treatment. Am J Clin Dermatol 2021; 22: 457-65.
Signore RJ. A pilot study of 5 percent permethrin cream versus 0.75 percent metronidazole gel in acne rosacea. Cutis. 1995; 56: 177-9.
Koçak M, Yag˘li S, Vahapog˘lu G, Eks¸iog˘lu M. Permethrin 5 % cream versus metronidazole 0.75 % gel for the treatment of papulopustular rosacea. A randomized double-blind placebo-controlled study. Dermatology 2002; 205: 265-70.
Raoufinejad K, Mansouri P, Rajabi M et al. Efficacy and safety of permethrin 5 % topical gel vs. placebo for rosacea: a double-blind randomized controlled clinical trial. J Eur Acad Dermatol Venereol 2016; 30: 2105-17.
Wilkin JK, DeWitt S. Treatment of rosacea: topical clindamycin versus oral tetracycline. Int J Dermatol 1993; 32: 65-7.
Martel P, Jarratt M, Weiss J, Carlavan I. Lack of significant anti-inflammatory activity with clindamycin in the treatment of rosacea: results of 2 randomized, vehicle-controlled trials. Cutis 2017; 100: 53-8.
Altinyazar HC, Koca R, Tekin NS, Es¸türk E. Adapalene vs. metronidazole gel for the treatment of rosacea. Int J Dermatol 2005; 44: 252-5.
Korting HC, Schöllmann C. Tetracycline actions relevant to rosacea treatment. Skin Pharmacol Physiol 2009; 22: 287-94.
Vienne MP, Ochando N, Borrel MT et al. Retinaldehyde alleviates rosacea. Dermatology 1999; 199 (Suppl 1): 53-6.
Garg G, Thami GP. Clinical efficacy of tacrolimus in rosacea. J Eur Acad Dermatol Venereol 2009; 23: 239-40.
Bamford JT, Elliott BA, Haller IV. Tacrolimus effect on rosacea. J Am Acad Dermatol 2004; 50: 107-8.
Pelle MT, Crawford GH, James WD. Rosacea: II. Therapy. J Am Acad Dermatol 2004; 51: 499-512; quiz 13-4.
Lee DH, Li K, Suh DH. Pimecrolimus 1 % cream for the treatment of steroid-induced rosacea: an 8-week split-face clinical trial. Br J Dermatol 2008; 158: 1069-76.
Chu CY. The use of 1 % pimecrolimus cream for the treatment of steroid-induced rosacea. Br J Dermatol 2005; 152: 396-9.
Cunha PR, Rossi AB. Pimecrolimus cream 1 % is effective in a case of granulomatous rosacea. Acta Derm Venereol 2006; 86: 71-2.
Koca R, Altinyazar HC, Ankarali H et al. A comparison of metronidazole 1 % cream and pimecrolimus 1 % cream in the treatment of patients with papulopustular rosacea: a randomized open-label clinical trial. Clin Exp Dermatol 2010; 35: 251-6.
Kim MB, Kim GW, Park HJ et al. Pimecrolimus 1 % cream for the treatment of rosacea. J Dermatol 2011; 38: 1135-9.
Teraki Y, Hitomi K, Sato Y, Izaki S. Tacrolimus-induced rosacea-like dermatitis: a clinical analysis of 16 cases associated with tacrolimus ointment application. Dermatology 2012; 224: 309-14.
Hu L, Alexander C, Velez NF et al. Severe tacrolimus-induced granulomatous rosacea recalcitrant to oral tetracyclines. J Drugs Dermatol 2015; 14: 628-30.
El-Heis S, Buckley DA. Rosacea-like eruption due to topical pimecrolimus. Dermatol Online J 2015; 21.
Oztürkcan S, Ermertcan AT, Sahin MT, Afşar FS. Efficiency of benzoyl peroxide-erythromycin gel in comparison with metronidazole gel in the treatment of acne rosacea. J Dermatol 2004; 31: 610-7.
Leyden JJ. Randomized, phase 2, dose-ranging study in the treatment of rosacea with encapsulated benzoyl peroxide gel. J Drugs Dermatol 2014; 13: 685-8.
Dahl MV, Katz HI, Krueger GG et al. Topical metronidazole maintains remissions of rosacea. Arch Dermatol 1998; 134: 679-83.
Sneddon IB. A clinical trial of tetracycline in rosacea. Br J Dermatol 1966; 78: 649-52.
Baldwin HE. Systemic therapy for rosacea. Skin Therapy Lett. 2007; 12: 1-5, 9.
Kanada KN, Nakatsuji T, Gallo RL. Doxycycline indirectly inhibits proteolytic activation of tryptic kallikrein-related peptidases and activation of cathelicidin. J Invest Dermatol 2012; 132: 1435-42.
Maibach H. Second-generation tetracyclines, a dermatologic overview: clinical uses and pharmacology. Cutis 1991; 48: 411-7.
Berman B, Perez OA, Zell D. Update on rosacea and anti-inflammatory-dose doxycycline. Drugs Today (Barc) 2007; 43: 27-34.
McKeage K, Deeks ED. Doxycycline 40 mg capsules (30 mg immediate-release/10 mg delayed-release beads): anti-inflammatory dose in rosacea. Am J Clin Dermatol 2010; 11: 217-22.
van Zuuren EJ, Fedorowicz Z, Carter B et al. Interventions for rosacea. Cochrane Database Syst Rev 2015; 2015: Cd003262.
Pfeffer I, Borelli C, Zierhut M, Schaller M. Treatment of ocular rosacea with 40 mg doxycycline in a slow release form. J Dtsch Dermatol Ges 2011; 9: 904-7.
Sobolewska B, Doycheva D, Deuter C et al. Treatment of ocular rosacea with once-daily low-dose doxycycline. Cornea 2014; 33: 257-60.
van der Linden MMD, van Ratingen AR, vanRappard DC et al. DOMINO, doxycycline 40 mg vs. minocycline 100 mg in the treatment of rosacea: a randomized, single-blinded, noninferiority trial, comparing efficacy and safety. Br J Dermatol 2017; 176: 1465-74.
Smith K, Leyden JJ. Safety of doxycycline and minocycline: a systematic review. Clin Ther 2005; 27: 1329-42.
Lebrun-Vignes B, Kreft-Jais C, Castot A, Chosidow O. Comparative analysis of adverse drug reactions to tetracyclines: results of a French national survey and review of the literature. Br J Dermatol 2012; 166: 1333-41.
Torresani C, Pavesi A, Manara GC. Clarithromycin versus doxycycline in the treatment of rosacea. Int J Dermatol 1997; 36: 942-6.
Bakar O, Demircay Z, Toker E, Cakir S. Ocular signs, symptoms and tear function tests of papulopustular rosacea patients receiving azithromycin. J Eur Acad Dermatol Venereol 2009; 23: 544-9.
Pye RJ, Burton JL. Treatment of rosacea by metronidazole. Lancet 1976; 1: 1211-2.
Lehmann P. [Rosacea. Clinical features, pathogenesis and therapy]. Hautarzt 2005; 56: 871-85; quiz 86-7.
Marks R, Ellis J. Comparative effectiveness of tetracycline and ampicillin in rosacea. A controlled trial. Lancet 1971; 2: 1049-52.
Drago F, De Col E, Agnoletti AF et al. The role of small intestinal bacterial overgrowth in rosacea: A 3-year follow-up. J Am Acad Dermatol 2016; 75: e113-e15.
Nikolowski J, Plewig G. [Rosacea. Oral therapy with 13-cis retinoic acid]. Hautarzt 1980; 31: 660-1.
Schmidt JB, Raff M. [13-Cis-retinoic acid: a new form of treatment of rosacea (author’s transl)]. Wien Klin Wochenschr 1982; 94: 115-8.
Marsden JR, Shuster S, Neugebauer M. Response of rosacea to isotretinoin. Clin Exp Dermatol 1984; 9: 484-8.
Hoting E, Paul E, Plewig G. Treatment of rosacea with isotretinoin. Int J Dermatol 1986; 25: 660-3.
Erdogan FG, Yurtsever P, Aksoy D, Eskioglu F. Efficacy of low-dose isotretinoin in patients with treatment-resistant rosacea. Arch Dermatol 1998; 134: 884-5.
Jansen T, Regele D, Schirren CG et al. [Persistent erythema and edema of the face associated with rosacea and lymph vessel dysplasia]. Hautarzt 1998; 49: 932-5.
Bostanci O, Borelli C, Schaller M. Treatment of extrafacial rosacea with low-dose isotretinoin. Acta Derm Venereol 2010; 90: 409-10.
Sbidian E, Vicaut É, Chidiack H et al. A Randomized-controlled trial of oral low-dose isotretinoin for difficult-to-treat papulopustular rosacea. J Invest Dermatol 2016; 136: 1124-9.
Melnik B, Jansen T. Akne und Rosazea. In: Plewig G, Landthaler M, Burgdorf: Braun-Falco’s Dermatologie, Venerologie Und Allergologie. 6th Edition. Berlin and Heidelberg: Springer-Verlag, 2012.
Hsu CC, Lee JY. Pronounced facial flushing and persistent erythema of rosacea effectively treated by carvedilol, a nonselective β-adrenergic blocker. J Am Acad Dermatol 2012; 67: 491-3.
Pietschke K, Schaller M. Long-term management of distinct facial flushing and persistent erythema of rosacea by treatment with carvedilol. J Dermatolog Treat 2018; 29: 310-3.
Craige H, Cohen JB. Symptomatic treatment of idiopathic and rosacea-associated cutaneous flushing with propranolol. J Am Acad Dermatol 2005; 53: 881-4.
Rodrigues-Braz D, Zhao M, Yesilirmak N et al. Cutaneous and ocular rosacea: Common and specific physiopathogenic mechanisms and study models. Mol Vis 2021; 27: 323-53.
Ghanem VC, Mehra N, Wong S, Mannis MJ. The prevalence of ocular signs in acne rosacea: comparing patients from ophthalmology and dermatology clinics. Cornea 2003; 22: 230-3.
Vieira AC, Höfling-Lima AL, Mannis MJ. Ocular rosacea - a review. Arq Bras Oftalmol 2012; 75: 363-9.
Moustafa F, Lewallen RS, Feldman SR. The psychological impact of rosacea and the influence of current management options. J Am Acad Dermatol 2014; 71: 973-80.
Oltz M, Check J. Rosacea and its ocular manifestations. Optometry 2011; 82: 92-103.
Lazaridou E, Fotiadou C, Ziakas NG et al. Clinical and laboratory study of ocular rosacea in northern Greece. J Eur Acad Dermatol Venereol 2011; 25: 1428-31.
Keshtcar-Jafari A, Akhyani M, Ehsani AH et al. Correlation of the severity of cutaneous rosacea with ocular rosacea. Indian J Dermatol Venereol Leprol 2009; 75: 405-6.
Palamar M, Degirmenci C, Ertam I, Yagci A. Evaluation of dry eye and meibomian gland dysfunction with meibography in patients with rosacea. Cornea 2015; 34: 497-9.
Machalińska A, Zakrzewska A, Markowska A et al. Morphological and functional evaluation of meibomian gland dysfunction in rosacea patients. Curr Eye Res 2016; 41: 1029-34.
Knop E, Knop N, Brewitt H et al. [Meibomian glands: part III. Dysfunction - argument for a discrete disease entity and as an important cause of dry eye]. Ophthalmologe 2009; 106: 966-79.
Carruth BP, Meyer DR, Wladis EJ et al. Extreme eyelid lymphedema associated with rosacea (Morbihan disease): case series, literature review, and therapeutic considerations. Ophthalmic Plast Reconstr Surg 2017; 33: S34-8.
Geerling G, Baudouin C, Aragona P et al. Emerging strategies for the diagnosis and treatment of meibomian gland dysfunction: Proceedings of the OCEAN group meeting. Ocul Surf 2017; 15: 179-92.
Shine WE, McCulley JP. Meibomianitis: polar lipid abnormalities. Cornea 2004; 23: 781-3.
Mizoguchi S, Iwanishi H, Arita R et al. Ocular surface inflammation impairs structure and function of meibomian gland. Exp Eye Res 2017; 163: 78-84.
Geerling G, Tauber J, Baudouin C et al. The international workshop on meibomian gland dysfunction: report of the subcommittee on management and treatment of meibomian gland dysfunction. Invest Ophthalmol Vis Sci 2011; 52: 2050-64.
Jones L, Downie LE, Korb D et al. TFOS DEWS II management and therapy report. Ocul Surf 2017; 15: 575-628.
Schechter BA, Katz RS, Friedman LS. Efficacy of topical cyclosporine for the treatment of ocular rosacea. Adv Ther 2009; 26: 651-9.
Haque RM, Torkildsen GL, Brubaker K et al. Multicenter open-label study evaluating the efficacy of azithromycin ophthalmic solution 1 % on the signs and symptoms of subjects with blepharitis. Cornea 2010; 29: 871-7.
Gonser LI, Gonser CE, Deuter C et al. Systemic therapy of ocular and cutaneous rosacea in children. J Eur Acad Dermatol Venereol 2017; 31: 1732-8.
Salem DA, El-Shazly A, Nabih N et al. Evaluation of the efficacy of oral ivermectin in comparison with ivermectin-metronidazole combined therapy in the treatment of ocular and skin lesions of Demodex folliculorum. Int J Infect Dis 2013; 17: e343-7.
Sobolewska B, Doycheva D, Deuter CM et al. Efficacy of topical ivermectin for the treatment of cutaneous and ocular rosacea. Ocul Immunol Inflamm 2021; 29: 1137-41.
Liu A, Ji J. Omega-3 essential fatty acids therapy for dry eye syndrome: a meta-analysis of randomized controlled studies. Med Sci Monit 2014; 20: 1583-9.
Asbell PA, Maguire MG, Pistilli M et al. n-3 fatty acid supplementation for the treatment of dry eye disease. N Engl J Med 2018; 378: 1681-90.
Liu S, Tang S, Dong H, Huang X. Intense pulsed light for the treatment of Meibomian gland dysfunction: A systematic review and meta-analysis. Exp Ther Med 2020; 20: 1815-21.
Verordnung (EG) nr. 1223/2009 des europäischen Parlaments und des Rates vom 30. November 2009 über kosmetische Mittel. Amtsblatt der Europäischen Union, 2009.
Dermopharmazie GGf. Interdisziplinäres Management der Rosazea. 2014.
Schaller M, Belge, K. Rosazea - Aktuelle Therapieoptionen im Blickpunkt. Hautnah Dermatologie 2013; 1: 27-33.
Kerscher M, Reuther T. Der Fluch der Kelten - Kosmetische Aspekte bei der Rosazea. In: Schöfer H (Hrsg) Rosazea. Klinik und aktuelle Therapie. Stuttgart: Thieme Verlag, 2003: 67-72.
Borelli C, Korting HC. Nichtmedikamentöses Management der Rosazea. Hautarzt 2011; 62: 828-33.
Draelos ZD, Colón LE, Preston N et al. The appearance of facial foundation cosmetics applied after metronidazole gel 1 %. Cutis. 2011; 87: 251-9.
Levin J, Miller R. A guide to the ingredients and potential benefits of over-the-counter cleansers and moisturizers for rosacea patients. J Clin Aesthet Dermatol 2011; 4: 31-49.
Del Rosso JQ. Adjunctive skin care in the management of rosacea: cleansers, moisturizers, and photoprotectants. Cutis 2005; 75: 17-21; discussion 33-6.
Raab W, Kindl U. Pflegekosmetik. Ein Leitfaden, 5. Aufl., Wissenschaftliche Verlagsgesellschaft, Stuttgart, 2012.
Draelos ZD. The effect of Cetaphil Gentle Skin Cleanser on the skin barrier of patients with rosacea. Cutis 2006; 77: 27-33.
Draelos Z, Hornby S, Walters RM, Appa Y. Hydrophobically modified polymers can minimize skin irritation potential caused by surfactant-based cleansers. J Cosmet Dermatol 2013; 12: 314-21.
Schmid-Wendtner MH, Korting HC. pH and skin care, ABW Wissenschaftsverlag, Berlin, 2007.
Kresken J, Kindl U, Wigger-Alberti W et al. Dermocosmetics for use in rosacea: guideline of the society for dermopharmacy. Skin Pharmacol Physiol 2018; 31: 147-54.
Guertler A, Jontvedt NM, Clanner-Engelshofen BM et al. Efficacy and safety results of micellar water, cream and serum for rosacea in comparison to a control group. J Cosmet Dermatol 2020; 19: 2627-33.
Wu JJ, Weinstein GD, Kricorian GJ et al. Topical kinetin 0.1 % lotion for improving the signs and symptoms of rosacea. Clin Exp Dermatol 2007; 32: 693-5.
Weber TM, Ceilley RI, Buerger A et al. Skin tolerance, efficacy, and quality of life of patients with red facial skin using a skin care regimen containing Licochalcone A. J Cosmet Dermatol 2006; 5: 227-32.
Seite S, Deshayes P, Dreno B et al. Interest of corrective makeup in the management of patients in dermatology. Clin Cosmet Investig Dermatol 2012; 5: 123-8.
Peuvrel L, Quereux G, Brocard A et al. Evaluation of quality of life after a medical corrective make-up lesson in patients with various dermatoses. Dermatology 2012; 224: 374-80.
Karagulle MZ, Karagulle M, Kilic S et al. In vitro evaluation of natural thermal mineral waters in human keratinocyte cells: a preliminary study. Int J Biometeorol 2018; 62: 1657-61.
Seite S. Thermal waters as cosmeceuticals: La Roche-Posay thermal spring water example. Clin Cosmet Investig Dermatol 2013; 6: 23-8.
Eliasse Y, Redoules D, Espinosa E. Impact of Avene Thermal Spring Water on immune cells. J Eur Acad Dermatol Venereol 2020; 34 (Suppl 5): 21-26.
Mias C, Maret A, Gontier E et al. Protective properties of Avene Thermal Spring Water on biomechanical, ultrastructural and clinical parameters of human skin. J Eur Acad Dermatol Venereol 2020; 34 (Suppl 5): 15-20.
Nocera T, Jean-Decoster C, Georgescu V, Guerrero D. Benefits of Avene thermal hydrotherapy in chronic skin diseases and dermatological conditions: an overview. J Eur Acad Dermatol Venereol 2020; 34 (Suppl 5): 49-52.